Should angiotensin-converting enzyme inhibitors and angiotensin receptor blockers be used in patients with or at risk of COVID-19?
This Viewpoint discusses recommendations for ACEi and ARB use in the context of COVID-19 infection.
This Viewpoint discusses recommendations for angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use in patients with or at risk of contracting coronavirus disease 2019 (COVID-19).
Bavishi et al. (Fri,) studied this question.